ATLAS Trial of Continuing Adjuvant Tamoxifen to 10 Years versus Stopping at 5 Years for Early Breast Cancer
Davies C et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet 2012;[Epub ahead of print]. Abstract
Dr Chlebowski is Professor of Medicine at David Geffen School of Medicine at UCLA and Chief of the Division of Medical Oncology and Hematology at Harbor-UCLA Medical Center in Torrance, California.
Sir Richard Peto is Professor of Medical Statistics and Co-director of the Clinical Trial Service Unit at the University of Oxford in Oxford, United Kingdom.
|